Total Payments
$38,862
2024 Payments
$292.22
Companies
6
Transactions
48
Medicare Patients
461
Medicare Billing
$62,725
Payment Breakdown by Category
Other$14,970 (38.5%)
Travel$10,465 (26.9%)
Research$9,329 (24.0%)
Consulting$3,082 (7.9%)
Food & Beverage$1,016 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,970 | 12 | 38.5% |
| Travel and Lodging | $10,465 | 10 | 26.9% |
| Unspecified | $9,329 | 6 | 24.0% |
| Consulting Fee | $3,082 | 3 | 7.9% |
| Food and Beverage | $1,016 | 17 | 2.6% |
Payments by Type
General
$29,533
42 transactions
Research
$9,329
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $23,971 | 17 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $13,300 | 25 | $0 (2023) |
| AstraZeneca UK Limited | $935.00 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $428.71 | 2 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $180.00 | 1 | $0 (2018) |
| Stemline Therapeutics Inc. | $47.51 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $292.22 | 3 | Novartis Pharmaceuticals Corporation ($209.71) |
| 2023 | $3,052 | 11 | PFIZER INC. ($1,900) |
| 2022 | $3,800 | 2 | PFIZER INC. ($3,800) |
| 2021 | $3,419 | 2 | PFIZER INC. ($3,200) |
| 2019 | $669.06 | 2 | PFIZER INC. ($620.00) |
| 2018 | $19,717 | 9 | PFIZER INC. ($10,861) |
| 2017 | $7,912 | 19 | PFIZER INC. ($3,590) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $47.51 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 02/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | — | Cash or cash equivalent | $209.71 | Research |
| Study: HEOR - LEE011-2016-PLS • Category: Oncology | ||||||
| 03/10/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $73.61 | General |
| 03/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $73.61 | General |
| 03/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $72.17 | General |
| 03/09/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $2.30 | General |
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $152.07 | General |
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $96.56 | General |
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $72.17 | General |
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $70.72 | General |
| 03/08/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $70.06 | General |
| 03/07/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $469.09 | General |
| 02/01/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/13/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/24/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,900.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/20/2021 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/09/2021 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $219.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR PIQRAY RESEARCH • Category: ONCOLOGY | ||||||
| 10/01/2019 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $620.00 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $49.06 | General |
| 12/03/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $180.00 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2018 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Travel and Lodging | Cash or cash equivalent | $8,676.38 | General |
| Category: Oncology | ||||||
| 07/10/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $780.00 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2018 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,900 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR PIQRAY RESEARCH | Novartis Pharmaceuticals Corporation | $219.00 | 1 |
| HEOR - LEE011-2016-PLS | Novartis Pharmaceuticals Corporation | $209.71 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 129 | 229 | $131,305 | $20,166 |
| 2022 | 3 | 105 | 204 | $109,640 | $16,667 |
| 2021 | 4 | 142 | 199 | $109,350 | $17,539 |
| 2020 | 3 | 85 | 134 | $61,970 | $8,352 |
Total Patients
461
Total Services
766
Medicare Billing
$62,725
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 149 | $81,205 | $12,524 | 15.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $31,350 | $4,756 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 50 | $18,750 | $2,886 | 15.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 124 | $67,580 | $10,483 | 15.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 62 | $23,250 | $3,336 | 14.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $18,810 | $2,848 | 15.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 95 | $51,775 | $8,682 | 16.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 59 | 69 | $25,875 | $3,610 | 14.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $20,900 | $3,337 | 16.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 15 | $10,800 | $1,910 | 17.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 55 | 100 | $52,000 | $7,123 | 13.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 19 | $6,745 | $864.24 | 12.8% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 12 | 15 | $3,225 | $364.98 | 11.3% |
About Dr. Mark Robson, MD
Dr. Mark Robson, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770554511.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Robson, MD has received a total of $38,862 in payments from pharmaceutical and medical device companies, with $292.22 received in 2024. These payments were reported across 48 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14,970).
As a Medicare-enrolled provider, Robson has provided services to 461 Medicare beneficiaries, totaling 766 services with total Medicare billing of $62,725. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 01/30/2006
- Last Updated 04/07/2015
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1770554511
Products in Payments
- TALZENNA (Drug) $20,280
- LYNPARZA (Drug) $11,903
- PIQRAY (Drug) $219.00
- KISQALI (Drug) $209.71
- KEYTRUDA (Biological) $180.00
- IBRANCE (Drug) $100.60
- Orserdu (Drug) $47.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555